Risk Factors Update Summary

• The company does not expect significant revenue from sotrovimab for COVID-19 treatment in the future.
• "Impact" replacing "constrain" regarding healthcare laws indicates a more severe effect on business arrangements. This change highlights potential financial risks.
• Addition of "7229" as a new product candidate suggests a specific focus on a different therapy area. This change may diversify the product portfolio and market opportunities.
• The company may not be able to recoup substantial financial resources committed to unsuccessful clinical trials.
• Addition of "licensed" to "biologic products" indicates a new licensing agreement. This change might result in expanded product offerings.
• Change from "physician-administered" to "certain" drugs indicates a broader scope of drugs for price negotiations. This change may impact pricing strategies and market access.
• The company may face delays or difficulties in clinical trials, impacting expenses and potential revenue.
• Change from "after the expiration" to "of applicable periods" suggests a specific regulatory exclusivity period. This change clarifies exclusivity duration.
• "Inflation Reduction" to "IRA" signifies a legislative change with implications for Medicare Part D. This change could affect pricing and reimbursement strategies.
• The company's ability to commercialize products successfully is uncertain, impacting revenue generation.
• Change from "BLA" to "regulatory approval" broadens the scope of approval beyond BLA. This change may impact market acceptance and reimbursement.
• The company's reliance on third parties for clinical supplies and studies poses risks to operations.
• The deployment of artificial intelligence in product development could adversely affect business outcomes.
• The company's lack of experience in certain areas may hinder successful commercialization efforts.